Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study

Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study

ObjectiveMucocutaneous and joint disorders are the most common manifestations in Behçet’s syndrome (BS) and are frequently clustered in the so-called minor forms of BS. There remains a need for safe and effective treatment for joint lesions in BS. We report the long-term safety and effectiveness of...

Full description

Bibliographic Details
Main Authors: Matheus Vieira, Solène Buffier, Mathieu Vautier, Alexandre Le Joncour, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurence Bouillet, Estibaliz Lazaro, Stéphane Barete, Laurent Misery, Delphine Gobert, Tiphaine Goulenok, Olivier Fain, Karim Sacre, Pascal Sève, Patrice Cacoub, Cloé Comarmond, David Saadoun
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
Behçet
apremilast
efficacy
safety
joint
skin
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.626792/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.626792/full

Similar Items